FrancophonIA/ELRC3.0 huggingface dataset:
English: Serious cardiovascular and cerebrovascular events, including myocardial infarction, angina pectoris, cerebrovascular accident and transient ischaemic attack have been uncommonly reported during clinical studies with pemetrexed, usually when given in combination with another cytotoxic agent.
Estonian: Pemetrekseedi kliiniliste uuringute ajal registreeriti aeg-ajalt, tavaliselt manustamisel koos teise tsütotoksilise ainega, raskeid kardiovaskulaarseid ja tserebrovaskulaarseid atakke, sh müokardiinfarkt, stenokardia, ajuinsult ja transitoorne ajuisheemia.
English: Excluding neurotoxicity
Estonian: Leukotsüütide vähenemine Neutrofiilide vähenemine
English: Inflammation of the lining of the oesophagus (gullet) has been experienced with Pemetrexed Fresenius Kabi / radiation therapy.
Estonian: Pemetrexed Fresenius Kabi / kiiritusravi ajal on täheldatud söögitoru sisepinna põletikku.
English: Each vial contains 100 mg of pemetrexed (as pemetrexed diacid).
Estonian: Üks viaal sisaldab 100 mg pemetrekseedi (pemetrekseed-diatsiidina).
English: NSCLC, first-line treatment
Estonian: Mitteväikerakk-kopsuvähk, esmavaliku ravi
English: Therefore, caution should be made when administering higher doses of NSAIDs or acetylsalicylic acid, concurrently with pemetrexed to patients with normal function (creatinine clearance > 80 ml/min).
Estonian: Normaalse neerufunktsiooniga patsientidel (kreatiniini kliirens ≥ 80 ml/min), kellele manustatakse pemetrekseedi, tuleb MSPVA või atsetüülsalitsüülhappe suuremaid annuseid kasutada ettevaatusega.
English: 19 January 2017 EMA/747766/2016
Estonian: 19. jaanuar 2017 EMA/747766/2016
English: This could lead to fluctuations in blood glucose control.
Estonian: See võib põhjustada vere glükoosisisalduse kõikumist.
English: • If you have any questions about your treatment, speak to your healthcare professional.
Estonian: • Kui teil on ravi kohta küsimusi, pidage nõu oma tervishoiutöötajaga.
English: Information for patients and carers
Estonian: Teave patsientidele ja hooldajatele
English: Measures intended to reduce risk of confusion between two pens of different strengths
Estonian: Meetmed, mille eesmärk on vähendada kahe eri tugevusega pensüstla segiajamise riski
English: Suliqua is a medicine that is used for the treatment of type-2 diabetes.
Estonian: Suliqua on ravim, mida kasutatakse II tüüpi diabeedi raviks.
English: More information about Suliqua can be found on the Agency's website: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004243/human_ med_002064.jsp
Estonian: Suliqua lisateave on EMA veebilehel: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/00424 3/human_med_002064.jsp
English: • When starting Suliqua and in the weeks thereafter you should measure your blood sugar levels more frequently than usual.
Estonian: • Suliqua kasutamise alguses ja järgnevatel nädalatel peate mõõtma oma vere glükoosisisaldust tavalisest sagedamini.
English: • Ensure that patients and their caretakers are adequately informed on how to use their medicine.
Estonian: • Veenduge, et patsiendid ja nende hooldajad on saanud piisavalt teavet, kuidas ravimit kasutada.
English: Before you use Suliqua be clear on how many dose steps you require.
Estonian: Enne Suliqua kasutamist selgitage välja, mitut annusesammu vajate.
English: • You must therefore not use the pens interchangeably as you could receive too much or too little lixisenatide and this could disrupt the control of your blood sugar levels.
Estonian: • Seetõttu ei tohi pensüstlaid kasutada vaheldumisi, sest nii võite manustada liksisenatiidi liiga palju või liiga vähe ja see võib häirida teie vere glükoosisisalduse reguleerimist.
English: Patients will receive a ‘patient guide' from their healthcare professional which they should read carefully along with the package leaflet.
Estonian: Patsiendid saavad tervishoiutöötajalt patsiendijuhendi, mille nad peavad koos pakendi infolehega hoolikalt läbi lugema.
English: To reduce the risk of medication errors, educational materials will be sent out to relevant healthcare professionals in the EU where the product is marketed, to raise awareness about the differences between the two pens, the way the dose is expressed and how to use the medicine correctly.
Estonian: Ravivigade ohu vähendamiseks saadetakse teabematerjalid asjaomastele tervishoiutöötajatele ELis, kus toodet turustatakse, et suurendada teadlikkust kahe pensüstla erinevuste, annuse esitamise viisi ja ravimi nõuetekohase kasutamise kohta.
English: • Explain the design and features of the pen to the patient and if the patient has been transferred from another pen device, highlight the differences in design between the two devices to avoid confusion (focus on colour differentiation, warning statements on carton/label).
Estonian: • Selgitage patsiendile pensüstla konstruktsiooni ja omadusi ning kui patsient kasutas varem teist penseadet, rõhutage segaduse vältimiseks kahe seadme konstruktsiooni erinevusi (värvierinevused, karbil/etiketil olevad hoiatused).
English: It is used for people needing 10-40 units of insulin daily.
Estonian: Seda kasutatakse patsientidel, kes vajavad ööpäevas 10-40 insuliiniühikut.
English: Your healthcare professional will give you this information.
Estonian: Selle teabe saate tervishoiutöötajalt.
English: • Tell patients to closely monitor their blood sugar levels when starting Suliqua and in the weeks thereafter.
Estonian: • Öelge patsientidele, et nad jälgiksid hoolikalt vere glükoosisisaldust Suliqua kasutamise alguses ja järgnevate nädalate jooksul.
English: It is used together with diabetes medicines taken by mouth in adults whose blood glucose (sugar) levels are not satisfactorily controlled by metformin alone or metformin combined with either a glucose-lowering medicine or insulin.
Estonian: Seda kasutatakse koos suukaudsete diabeediravimitega täiskasvanutel, kelle vere glükoosisisaldus (nn veresuhkur) ei ole ainult metformiini või metformiini ja glükoositaset alandava ravimi või insuliiniga piisavalt reguleeritud.
English: The lixisenatide strength is lower to ensure an adequate but not excessive dose in people requiring higher doses of insulin.
Estonian: Liksisenatiidi tugevus on väiksem, et tagada piisav, aga mitte liiga suur annus neile, kes vajavad insuliini suuremates annustes.
English: • Suliqua is supplied in a pre-filled pen and must only be used with this device.
Estonian: • Suliquat turustatakse eeltäidetud pensüstlas ja seda tohib kasutada ainult selle seadmega.
English: • Patients who are blind or with poor vision must be instructed to always get assistance from another person who has good vision and is trained in using the Suliqua pen device.
Estonian: • Nägemispuude või nägemisprobleemiga patsientidele tuleb rõhutada, et nad paluksid alati abi teiselt inimeselt, kelle nägemine on korras ja kes on õppinud Suliqua pensüstalt kasutama.
English: One dose step always contains one unit of insulin, regardless of the Suliqua pen being used.
Estonian: Üks annusesamm sisaldab alati ühte insuliiniühikut olenemata sellest, millist Suliqua pensüstalt kasutatakse.
English: It is available as a solution for injection in pre-filled pens.
Estonian: Seda turustatakse süstelahusena eeltäidetud pensüstaldes.
English: Healthcare professionals should ensure that they train their patients on how to use Suliqua correctly.
Estonian: Tervishoiutöötajad peavad õpetama oma patsientidele Suliqua nõuetekohast kasutusviisi.
English: Pharmacists should also check that patients have been trained on how to use the pen.
Estonian: Samuti tuleb kontrollida, kas patsiendid on saanud pensüstla kasutamise väljaõppe.
English: • Read the instructions in your package leaflet carefully before using your medicine.
Estonian: • Enne ravimi kasutamist lugege pakendi infolehe juhised hoolikalt läbi.
English: Healthcare professionals and patients expected to use the diabetes medicine Suliqua will be given educational materials to ensure that the medicine is used correctly and prevent medication errors such as confusion between the two different strengths of the product.
Estonian: Diabeediravimit Suliqua eeldatavalt kasutama hakkavatele tervishoiutöötajatele ja patsientidele antakse teabematerjalid, et tagada ravimi nõuetekohane kasutamine ja vältida ravivigu, nagu näiteks toote kahe eri tugevuse segiajamist.
English: • Provide patients with the patient guide prior to prescribing or dispensing Suliqua.
Estonian: • Andke patsientidele enne Suliqua väljakirjutamist või väljastamist patsiendijuhend.
English: A syringe must never be used to withdraw insulin glargine and lixisenatide from the pre-filled pen as this may lead to dosing errors and serious harm.
Estonian: Glargiin-insuliini ja liksisenatiidi ei tohi kunagi süstlaga eeltäidetud pensüstlast eemaldada, sest see võib põhjustada annustamisvigu ja tõsist kahju.
English: You must never use a syringe to remove the medicine from its pen as this may lead to dosing errors and serious harm.
Estonian: Ravimit ei tohi kunagi süstlaga pensüstlast eemaldada, sest see võib põhjustada annustamisvigu ja tõsist kahju.
English: • Pharmacists should clarify with the prescriber any incomplete prescription.
Estonian: • Apteekrid peavad küsima mittetäieliku retsepti kohta selgitusi ravimi väljakirjutajalt.
English: The doses of insulin and lixisenatide contained in increasing dose steps are given in the figure below:
Estonian: Kasvavates annusesammudes sisalduvad insuliini ja liksisenatiidi annused on esitatud allpool joonisel:
English: The lixisenatide strength is higher to ensure an adequate dose in people requiring lower doses of insulin.
Estonian: Liksisenatiidi tugevus on suurem, et tagada piisav annus neile, kes vajavad insuliini väiksemates annustes.
English: • Suliqua must only be used with its pre-filled pen.
Estonian: • Suliquat tohib kasutada ainult eeltäidetud pensüstlaga.
English: Suliqua is available in two different pens:
Estonian: Suliquat turustatakse kahe eri pensüstlana:
English: • Suliqua is supplied in two pre-filled pens:
Estonian: • Suliquat turustatakse kahe eeltäidetud pensüstlana:
English: • Because the two pens contain different concentrations of lixisenatide, the dose step of one pen is not equivalent to the dose step of the other.
Estonian: • Et kaks pensüstalt sisaldavad erinevas kontsentratsioonis liksisenatiidi, ei ole ühe pensüstla annusesamm võrdne teise pensüstla annusesammuga.
English: As for similar combination medicines used for the treatment of diabetes, the dose of Suliqua is expressed in ‘dose steps', with each dose step corresponding to one unit of insulin plus a fixed amount of lixisenatide.
Estonian: Nii nagu sarnastel kombineeritud diabeediravimitel, esitatakse Suliqua annus annusesammudena, kusjuures iga samm vastab ühele insuliiniühikule, millele on lisatud kindel kogus liksisenatiidi.
English: Your healthcare professional will train you on how to use the pen.
Estonian: Tervishoiutöötaja õpetab teid pensüstalt kasutama.
English: The amount of lixisenatide per dose step however varies (0.50 micrograms per dose step for the 10-40 pen and 0.33 micrograms per dose step for the 30-60 pen).
Estonian: Liksisenatiidi kogus annusesammus varieerub (0,50 µg annusesammu kohta 10-40 pensüstlas ja 0,33 µg annusesammu kohta 30-60 pensüstlas).
English: • Suliqua is a fixed combination of insulin glargine/lixisenatide available in two strengths:
Estonian: • Suliqua on glargiin-insuliini ja liksisenatiidi fikseeritud kombinatsioon, mida turustatakse kahe tugevusega:
English: • As for similar medicines containing insulin with a non-insulin medicine, the dose is expressed in dose steps.
Estonian: • Nii nagu sarnaste insuliini ja insuliini mittesisaldavat ravimit sisaldavate toodete korral, esitatakse annus annusesammudena.
English: • Explain to your patient that the dose counter of the pen device shows the number of dose steps to be injected.
Estonian: • Selgitage patsiendile, et pensüstla annuseloendur näitab süstitavate annusesammude arvu.
English: The active substances in Suliqua are insulin glargine and lixisenatide.
Estonian: Suliqua toimeained on glargiin-insuliin ja liksisenatiid.
English: • Pharmacists are encouraged to check that patients and carers are able to read the strength of Suliqua, the dose range of the pre-filled pen and the dose counter of the pen device before dispensing Suliqua.
Estonian: • Apteekrid peavad enne Suliqua väljastamist kontrollima, kas patsiendid ja hooldajad oskavad lugeda Suliqua tugevust, eeltäidetud pensüstla annusevahemikku ja annuseloendurit.
English: The prescription must state the type of pen to be used (either Suliqua 10-40 or Suliqua 30-60), the strength (i.e. insulin glargine 100 units/ml + lixisenatide 50 micrograms/ml or insulin glargine 100 units/ml + lixisenatide 33 micrograms/ml) and the number of dose steps to be administered.
Estonian: Retseptil tuleb märkida kasutatava pensüstla liik (kas Suliqua 10-40 või Suliqua 30-60), tugevus (st glargiin-insuliin 100 ühikut/ml + liksisenatiid 50 µg/ml või glargiin-insuliin 100 ühikut/ml + liksisenatiid 33 µg/ml) ja manustatavate annusesammude arv.
English: One dose step always contains one unit of insulin plus a fixed amount of lixisenatide.
Estonian: Üks annusesamm sisaldab alati ühte insuliiniühikut ja lisaks kindlas koguses liksisenatiidi.
English: deliver between 30 and 60 dose steps per day (and is also referred to as Suliqua 30-60) Since the two pens contain different amounts of lixisenatide for each dose step, it is important that they are not used interchangeably as this would result in patients receiving too much or too little lixisenatide.
Estonian: Et kaks pensüstalt sisaldavad igas annusesammu kohta erinevas koguses liksisenatiidi, on oluline, et neid ei kasutataks vaheldumisi, sest nii võivad patsiendid saada liiga palju või liiga vähe liksisenatiidi.
English: • Suliqua is given in dose steps which correspond to a set number of units of insulin plus a fixed amount of lixisenatide.
Estonian: • Suliquat manustatakse annusesammudena, mis vastavad kindlale arvule insuliiniühikutele ja kindlale liksisenatiidi kogusele.
English: • Suliqua contains insulin glargine and a non-insulin medicine, lixisenatide.
Estonian: • Suliqua sisaldab glargiin-insuliini ja insuliini mittesisaldavat ravimit liksisenatiidi.
English: Suliqua contains a combination of insulin glargine and a non-insulin medicine, lixisenatide.
Estonian: Suliqua on glargiin-insuliini ja insuliini mittesisaldava ravimi liksisenatiidi kombinatsioon.
English: • The dose counter of the pen device shows the number of dose steps to be injected.
Estonian: • Pensüstla annuseloendur näitab süstitavate annusesammude arvu.
English: − Suliqua 30-60 (containing insulin glargine 100 units/ml with lixisenatide 33 micrograms/ml)this pen can deliver between 30 and 60 dose steps per day.
Estonian: − Suliqua 30-60 (sisaldab 100 ühikut/ml glargiin-insuliini ja 33 µg/ml liksisenatiidi); selle pensüstlaga saab manustada 30-60 annusesammu ööpäevas.
English: Suliqua 10-40 (containing insulin glargine 100 units/ml with lixisenatide 50 micrograms/ml) - this pen can deliver between 10 and 40 dose steps per day.
Estonian: Suliqua 10-40 (sisaldab 100 ühikut/ml glargiin-insuliini ja 50 µg/ml liksisenatiidi); selle pensüstlaga saab manustada 10-40 annusesammu ööpäevas.
English: − Suliqua 10-40 (containing insulin glargine 100 units/ml with lixisenatide 50 micrograms/ml)this pen can deliver between 10 and 40 dose steps per day.
Estonian: − Suliqua 10-40 (sisaldab 100 ühikut/ml glargiin-insuliini ja 50 µg/ml liksisenatiidi); selle pensüstlaga saab manustada 10-40 annusesammu ööpäevas.
English: It has been available in the EU since the 1950s.
Estonian: Metformiini on Euroopa Liidus turustatud alates 1950. aastatest.
English: What measures are being taken to ensure the safe and effective use of Xigduo?
Estonian: Mis meetmed võetakse, et tagada Xigduo ohutu ja efektiivne kasutamine?
English: Further information on Xigduo can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/xigduo.
Estonian: Lisateave Xigduo kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/xigduo.
English: Xigduo received a marketing authorisation valid throughout the EU on 16 January 2014.
Estonian: Xigduo on saanud müügiloa, mis kehtib kogu ELis, 16. jaanuaril 2014.
English: The majority of these data had already been used in the authorisation of Forxiga.
Estonian: Andmetest enamikku kasutati juba Forxiga müügiloa taotlemisel.
English: As for all medicines, data on the use of Xigduo are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, tehakse Xigduo kasutamise kohta pidevat järelevalvet.
English: Other information about Xigduo
Estonian: Muu teave Xigduo kohta
English: What is Xigduo and what is it used for?
Estonian: Mis on Xigduo ja milleks seda kasutatakse?
English: The European Medicines Agency decided that Xigduo's benefits are greater than its risks and recommended that it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Xigduo kasulikkus on suurem kui sellega kaasnevad riskid ja ravimi kasutamise võib ELis heaks kiita.
English: Xigduo (dapagliflozin / metformin)
Estonian: Xigduo (dapagliflosiin/metformiin)
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Xigduo have been included in the summary of product characteristics and the package leaflet.
Estonian: Xigduo ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: For further information about using Xigduo, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Xigduo kasutamise kohta saate pakendi infolehelt või küsige oma arstilt või apteekrilt.
English: • in combination with other diabetes medicines when these medicines together with metformin are not controlling the diabetes well enough.
Estonian: • koos muude diabeediravimitega, kui need ravimid koos metformiiniga ei reguleeri diabeeti piisavalt.
English: Why is Xigduo authorised in the EU?
Estonian: Miks Xigduo ELis heaks kiideti?
English: such as dehydration, severe infection or shock;
Estonian: raske infektsioon või šokk;
English: Side effects reported with Xigduo are carefully evaluated and any necessary action taken to protect patients.
Estonian: Xigduo kõrvalnähte hinnatakse hoolikalt ja patsientide kaitseks võetakse vajalikke meetmeid.
English: • patients with diabetic precoma (a dangerous condition that can occur in diabetes);
Estonian: • diabeetiline eelkooma (ohtlik seisund, mis võib esineda diabeedi korral);
English: Xigduo contains two different active substances, which work in different ways:
Estonian: Xigduo sisaldab kaht toimeainet, mille toimemehhanismid on erinevad.
English: What are the risks associated with Xigduo?
Estonian: Mis riskid Xigduoga kaasnevad?
English: Xigduo can also be used to replace dapagliflozin and metformin taken as separate tablets.
Estonian: Xigduot tohib kasutada ka eraldi tablettidena võetava dapagliflosiini ja metformiini asendamiseks.
English: Dapagliflozin has been authorised in the European Union (EU) as Forxiga since 2012;
Estonian: Dapagliflosiinil on Euroopa Liidus müügiluba ravimina Forxiga alates 2012. aastast.
English: • on its own in patients whose disease is not controlled well enough with metformin alone;
Estonian: • ainuravimina patsientidel, kelle haigust ei reguleeri metformiin ainuravimina piisavalt;
English: As a result of the action of both active substances, the blood glucose is reduced and this helps to control type 2 diabetes.
Estonian: Mõlema toimeaine mõjul vere glükoosisisaldus väheneb ning see aitab 2. tüüpi diabeeti reguleerida.
English: • patients who are intoxicated with alcohol (drunkenness) or who regularly drink excessive amounts of alcohol.
Estonian: • alkoholijoobes või regulaarselt alkoholi liigtarbivad patsiendid.
English: • metformin works mainly by reducing glucose production and reducing its absorption from the gut.
Estonian: • Metformiini toime seisneb põhiliselt glükoosi tekke pärssimises ja selle sooles imendumise vähendamises.
English: Dapagliflozin in combination with metformin was evaluated in 6 main studies involving 3,200 adults with type 2 diabetes.
Estonian: Dapagliflosiini ja metformiini kombinatsiooni hinnati 6 põhiuuringus, kus osales 3200 2. tüüpi diabeediga täiskasvanut.
English: HbA1c (glycosylated haemoglobin) is a substance in the blood which gives an indication of how well the blood glucose is controlled.
Estonian: Veres sisalduv HbA1c (glükohemoglobiin) on aine, mis näitab, kui hästi vere glükoosisisaldus on reguleeritud.
English: The Agency also noted that giving the combination of dapagliflozin and metformin as a single tablet could provide an additional treatment option for patients with type 2 diabetes, and may improve adherence to treatment.
Estonian: Amet märkis ka, et dapagliflosiini ja metformiini kombinatsiooni võtmine ühe tabletina võib pakkuda 2. tüüpi diabeediga patsientidele uue ravivõimaluse ja parandada ravirežiimi järgimist.
English: Xigduo is available as tablets containing 5 mg of dapagliflozin with 850 mg of metformin and as 5 mg of dapagliflozin with 1,000 mg of metformin.
Estonian: Xigduot turustatakse tablettidena, mis sisaldavad 5 mg dapagliflosiini ja 850 mg metformiini, ning tablettidena, mis sisaldavad 5 mg dapagliflosiini ja 1000 mg metformiini.
English: It contains the active substances dapagliflozin and metformin.
Estonian: See sisaldab kaht toimeainet, dapagliflosiini ja metformiini.
English: Type 2 diabetes is a disease in which the pancreas does not make enough insulin to control the amount of glucose (sugar) in the blood or when the body cannot use insulin effectively.
Estonian: 2. tüüpi diabeet on haigus, mille korral kõhunäärmes ei teki vere glükoosisisalduse reguleerimiseks piisavalt insuliini või organism ei suuda insuliini efektiivselt kasutada.
English: When Xigduo is added to treatment with insulin or a medicine that helps the body to produce insulin, such as a sulphonylurea, the doctor may need to lower the dose of insulin or sulphonylurea to prevent hypoglycaemia (low blood sugar levels).
Estonian: Kui Xigduot lisatakse insuliinile või ravimile, mis aitab organismil toota insuliini, näiteks sulfonüüluurearavimile, võib arst hüpoglükeemia (vere väikese glükoosisisalduse) ennetamiseks vähendada insuliini või sulfonüüluurearavimi annust.
English: Regarding its safety profile, this was considered similar to the safety profile of dapagliflozin.
Estonian: Ravimi ohutusprofiili peeti sarnaseks dapagliflosiini ohutusprofiiliga.
English: • patients with any form of acute metabolic acidosis (build up of acid in the blood), such as diabetic ketoacidosis (high blood levels of acids called ‘ketones') or lactic acidosis (build-up of lactic acid in the body);
Estonian: • mis tahes vormis äge metaboolne atsidoos (vere happesisalduse suurenemine), näiteks diabeetiline ketoatsidoos (teatud hapete ketoonide suur sisaldus veres) või laktatsidoos (piimhappe kogunemine organismis);
English: How does Xigduo work?
Estonian: Kuidas Xigduo toimib?
English: Xigduo is a diabetes medicine used, together with diet and exercise in adults with type 2 diabetes.
Estonian: Xigduo on diabeediravim ning seda kasutatakse koos dieedi ja füüsilise koormusega 2. tüüpi diabeediga täiskasvanutel.
English: A long-term study, involving over 17,000 patients with type 2 diabetes, looked at the effects of dapagliflozin on cardiovascular (heart and circulation) disease.
Estonian: Ühes pikaajalises uuringus, milles osales üle 17 000 2. tüüpi diabeediga patsienti, uuriti dapagliflosiini toimet südame-veresoonkonnahaigusele.
English: How is Xigduo used?
Estonian: Kuidas Xigduot kasutatakse?
English: The most common side effects with Xigduo (which may affect more than 1 in 10 people) are hypoglycaemia (when used together with insulin or a sulphonylurea) and gastrointestinal symptoms (symptoms affecting the stomach and gut).
Estonian: Xigduo kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on hüpoglükeemia (kasutamisel koos insuliini või sulfonüüluurearavimiga) ja seedetraktiga seotud sümptomid (mao- ja soolesümptomid).